WITHDRAWN: Irinotecan plus Weekly 5-Fluorouracil and Leucovorin as Salvage Treatment for Patients with Metastatic Colorectal Cancer: A Phase II Trial | Zendy

John Souglakos | Zendy; N. Vardakis | Zendy; N. Androulakis | Zendy; Stylianos Kakolyris | Zendy; C. Kourousis | Zendy; D. Mavroudis | Zendy; Athanasios Pallis | Zendy; Sofia Agelaki | Zendy; Kostas Kalbakis | Zendy; Vassilis Georgoulias | Zendy

Open Access

WITHDRAWN: Irinotecan plus Weekly 5-Fluorouracil and Leucovorin as Salvage Treatment for Patients with Metastatic Colorectal Cancer: A Phase II Trial

Author(s) -

John Souglakos,

N. Vardakis,

N. Androulakis,

Stylianos Kakolyris,

C. Kourousis,

D. Mavroudis,

Athanasios Pallis,

Sofia Agelaki,

Kostas Kalbakis,

Vassilis Georgoulias

Publication year - 2007

Publication title -

digestive diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.879

H-Index - 66

eISSN - 1421-9875

pISSN - 0257-2753

DOI - 10.1159/000099177

Subject(s) - medicine , irinotecan , neutropenia , regimen , fluorouracil , chemotherapy , oxaliplatin , colorectal cancer , gastroenterology , salvage therapy , surgery , progressive disease , phases of clinical research , performance status , febrile neutropenia , toxicity , folfiri , cancer

A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan/5-fluorouracil/leucovorin (CPT-11/5-FU/LV (AIO schedule)) as salvage treatment in patients with metastatic colorectal cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research